These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37060587)

  • 1. Monoclonal Antibody Therapy in Autoantibody-Associated Psychotic Disorders and Schizophrenia: Narrative Review of Past and Current Clinical Trials.
    Hansen N; Malchow B
    Psychiatr Danub; 2023; 35(1):8-15. PubMed ID: 37060587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol for a randomized controlled trial with rituximab for psychotic disorder in adults (RCT-Rits).
    Bejerot S; Eklund D; Hesser H; Hietala MA; Kariis T; Lange N; Lebedev A; Montgomery S; Nordenskjöld A; Petrovic P; Söderbergh A; Thunberg P; Wikström S; Humble MB;
    BMC Psychiatry; 2023 Oct; 23(1):771. PubMed ID: 37872497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Wang X; Zhao J; Hu Y; Jiao Z; Lu Y; Ding M; Kou Y; Li B; Meng F; Zhao H; Li H; Li W; Yang Y; Lv L
    Psychiatry Res; 2018 Nov; 269():271-277. PubMed ID: 30170285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Stone JM; Morrison PD; Koychev I; Gao F; Reilly TJ; Kolanko M; Mohammadinasab A; Kapur S; McGuire PK
    Psychol Med; 2016 Dec; 46(16):3443-3450. PubMed ID: 27655012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell-targeted therapy for systemic lupus erythematosus: an update.
    Ding C; Foote S; Jones G
    BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.
    Nasib LG; Sommer IE; Winter-van Rossum I; de Vries J; Gangadin SS; Oomen PP; Judge G; Blom RE; Luykx JJ; van Beveren NJM; Veen ND; Kroken RA; Johnsen EL
    Trials; 2020 Jun; 21(1):492. PubMed ID: 32513294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial).
    Morozova M; Burminskiy D; Rupchev G; Lepilkina T; Potanin S; Beniashvili A; Lavrovsky Y; Vostokova N; Ivaschenko A
    J Clin Psychopharmacol; 2017 Apr; 37(2):169-175. PubMed ID: 28141622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.
    Lerner V; Miodownik C; Kaptsan A; Cohen H; Loewenthal U; Kotler M
    J Clin Psychiatry; 2002 Jan; 63(1):54-8. PubMed ID: 11838627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia.
    Pierre JM; Peloian JH; Wirshing DA; Wirshing WC; Marder SR
    J Clin Psychiatry; 2007 May; 68(5):705-10. PubMed ID: 17503979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.
    Weiser M; Levi L; Burshtein S; Chiriță R; Cirjaliu D; Gonen I; Yolken R; Davidson M; Zamora D; Davis JM
    Schizophr Res; 2019 Apr; 206():325-332. PubMed ID: 30455075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
    Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM
    CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.